In the last trading session, 0.99 million Aptevo Therapeutics Inc (NASDAQ:APVO) shares changed hands as the company’s beta touched 4.99. With the company’s per share price at $0.19 changed hands at $0.01 or 4.40% during last session, the market valuation stood at $3.35M. APVO’s last price was a discount, traded about -3689.47% off its 52-week high of $7.20. The share price had its 52-week low at $0.15, which suggests the last value was 21.05% up since then. When we look at Aptevo Therapeutics Inc’s average trading volume, we note the 10-day average is 0.83 million shares, with the 3-month average coming to 462.44K.
Analysts gave the Aptevo Therapeutics Inc (APVO) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended APVO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Aptevo Therapeutics Inc’s EPS for the current quarter is expected to be -$0.41.
Aptevo Therapeutics Inc (NASDAQ:APVO) trade information
Instantly APVO was in green as seen at the end of in last trading. With action 7.35%, the performance over the past five days has been green. The jump to weekly highs of 0.2159 on Friday, 11/17/23 added 4.40% to the stock’s daily price. The company’s shares are showing year-to-date downside of -91.81%, with the 5-day performance at 7.35% in the green. However, in the 30-day time frame, Aptevo Therapeutics Inc (NASDAQ:APVO) is -44.77% down. Looking at the short shares, we see there were 0.1 million shares sold at short interest cover period of 0.14 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7.38, meaning bulls need an upside of 97.43% from its current market value. According to analyst projections, APVO’s forecast low is $4.75 with $10.00 as the target high. To hit the forecast high, the stock’s price needs a -5163.16% plunge from its current level, while the stock would need to soar -2400.0% for it to hit the projected low.
Aptevo Therapeutics Inc (APVO) estimates and forecasts
Data shows that the Aptevo Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -88.82% over the past 6 months, a 72.13% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Aptevo Therapeutics Inc will rise 56.80%, while the growth in revenue is estimated to hit -192.30% for the next quarter.
The 2023 estimates are for Aptevo Therapeutics Inc earnings to decrease by -262.41%.
Aptevo Therapeutics Inc is expected to release its next quarterly earnings report on November 14.